Crestor (rosuvastatin) is the first statin to receive FDA approval for primary prevention

Crestor (rosuvastatin) is the first statin to receive FDA approval for primary prevention of heart disease. According to MedPageToday, the indication is for the following:

The new indication would be for men 50 or older and women 60 or older who have fasting LDL of less than 130 mg/dL, a highly-sensitive CRP of 2.0 mg/L or greater, triglycerides of less than 500 mg/dL, and no prior history of heart attack or stroke, or coronary heart disease risk.

The FDA has been discussing the results of a significant study called the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) study. The results of the JUPITER study were published in the New England Journal of Medicine in November 2008 (and since it's now in the public domain, you can click here to read the full study). Considering that this is a paradigm shift regarding the use of statins, the FDA wanted plenty of time to go through the data before they approve a new indication.

The funny thing is that my wife and I were talking about primary prevention, normal lipid levels, hs-CRP, and primary prevention the other day. My cholesterol levels are fine, but what about my hs-CRP? Should I be on a statin? Any statin, or a specific statin?

Crestor (rosuvastatin) in marketed by AstraZeneca.

FDA panel backs new use for AstraZeneca's Crestor

FDA panel backs new use for AstraZeneca's Crestor

12/15/2009, 5:56 p.m. EST

By MATTHEW PERRONE (AP)

GAITHERSBURG, Md. — Federal health advisers said Tuesday that expanded use of AstraZeneca's cholesterol pill Crestor can benefit patients with healthy cholesterol levels by preventing heart attack, stroke and death.
A Food and Drug Administration panel of experts voted 12-4 with one abstention that Crestor's benefits outweigh its risks in patients with normal cholesterol and no history of heart disease, setting the stage for a dramatic expansion of a drug that is already a blockbuster.
The FDA is not required to follow the group's advice, though it usually does. A decision is expected in the first quarter of next year.

(read more...)

Misguided health article on CNN about CRP

CNN has a story that has a misguided title (in my opinion). The story is titled, "Study suggests C-reactive protein doesn't cause heart disease." If we focus on causality, we may be missing the boat.

C-reactive protein (CRP) may not cause heart disease, but it may be a marker of underlying inflammation. Chronic inflammation may lead to coronary heart disease (CHD). If that's all true, then the title of the story can be misguiding. We often think in terms of cause and effect. If you have blood stasis (not moving), then you can form a blood clot. Cause and effect. So, if cardiovascular inflammation causes CHD, can you have inflammation without an elevation in CRP? Can you also develop CHD without any inflammation if you also have really high cholesterol levels? I think we're learning that the pathophysiology of CHD is not as simple as we learned about in medical school.

Well, if CRP doesn't cause heart disease, so what? What if CRP is an indicator of heart disease? That's the real question. It may not have a causal relationship, but that statement may be misguiding.

The JUPITER study published in the New England Journal of Medicine (NEJM) showed that a cholesterol-lowering drug Crestor (rosuvastatin) significantly reduced the incidence of major cardiovascular events in healthy-appearing patients who had low and normal cholesterol levels. This was such a groundbreaking study that it stirred significant controversy about CRP and the high-sensitivity CRP (hs-CRP).

CNN quotes the lead author of the JUPITER study in this story as "Another leading CRP researcher who isn't so sure about the findings published in the Journal of the American Medical Association (JAMA)." Dr. Paul M. Ridker, the director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, in Boston, Massachusetts, said: "A null Mendelian randomization may not mean very much... While it does not support causality, I don't think most genetic statisticians believe it excludes a causal pathway either."

Are you familiar with Mendelian Randomization and Genetic Association Studies? Good, me too. The JAMA studied used this as one of its steps: " A mendelian randomization study for the most associated single-nucleotide polymorphism (SNP) in the CRP locus in our data together with published data on CRP variants with CHD let us assess the potential causal association of CRP with CHD." Did you catch all that? Good, me too.

Dr. Ridker argues that clinicians should still measure hs-CRP for the following reasons:

• A, it predicts vascular risk even when cholesterol is low and other risk factors are absent, and,
  
• B, because we have clinical trial data demonstrating that if you have an increased level of [hs-CRP], you will live longer and have fewer heart attacks and strokes if you take a statin.

Dr. Ridker goes on to say: "I have always felt that CRP is a good clinical biomarker of inflammation (and high vascular risk) but that it is inflammation that is likely to be causal for atherosclerosis, not CRP itself." To read the CNN story, click here.

High Sensitivity C-Reactive Protein (hsCRP)

What do you know about hsCRP (high sensitivity C-Reactive protein, also abbreviated as hs-CRP)? Don't get confused now. hsCRP is not the same as standard CRP. Perhaps you're familiar with the JUPITER study published in the New England Journal of Medicine (NEJM). The conclusion from that study reads: "In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events."

Here are some interesting facts from the makers of the hsCRP assay:

C-reactive protein (CRP) is an acute phase protein that appears in circulation in response to inflammatory cytokines, such as interleukin-6, and serves as a biomarker for systemic inflammation. Following a systematic review of the association between inflammatory markers and coronary heart disease and stroke, the American Heart Association (AHA) and Centers for Disease Control and Prevention (CDC) developed a scientific statement that recommends hsCRP as a more sensitive assay for the prediction of vascular disease, compared to traditional assays for circulating C-reactive protein levels.

The AHA/CDC Scientific Statement Summary

• hsCRP is a global indicator of future vascular events in adults without any previous history of cardiovascular disease (CVD), with acceptable precision levels down to or below 0.3 mg/L
• hsCRP enhances risk assessment and therapeutic outcomes in primary CVD prevention
• hsCRP is particularly advantageous for assessing the risk in patients with
  • Framingham 10-year risk scores of 10%-20% and/or
  • LDL levels of <160>
• hsCRP acts as an independent marker for evaluating the possibility of recurrent cardiac events, such as myocardial infarction or restenosis, after percutaneous coronary intervention

AHA/CDC risk assessment guidelines

Low risk	<1>
Average risk	1-3 mg/L
High risk	>3 mg/L

Do you feel like you're an expert now? Click here to view the abstract for the JUPITER trial in the NEJM.